PT1009767E - Defensina humana def-x, gene e cdna, composicao que os contem e aplicacoes ao diagnostico e a terapia - Google Patents

Defensina humana def-x, gene e cdna, composicao que os contem e aplicacoes ao diagnostico e a terapia

Info

Publication number
PT1009767E
PT1009767E PT98942796T PT98942796T PT1009767E PT 1009767 E PT1009767 E PT 1009767E PT 98942796 T PT98942796 T PT 98942796T PT 98942796 T PT98942796 T PT 98942796T PT 1009767 E PT1009767 E PT 1009767E
Authority
PT
Portugal
Prior art keywords
def
cdna
diagnosis
therapy
gene
Prior art date
Application number
PT98942796T
Other languages
English (en)
Inventor
Ilya Chumakov
Lydie Bougueleret
Original Assignee
Genset Sa
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Genset Sa filed Critical Genset Sa
Publication of PT1009767E publication Critical patent/PT1009767E/pt

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61Q—SPECIFIC USE OF COSMETICS OR SIMILAR TOILETRY PREPARATIONS
    • A61Q17/00—Barrier preparations; Preparations brought into direct contact with the skin for affording protection against external influences, e.g. sunlight, X-rays or other harmful rays, corrosive materials, bacteria or insect stings
    • A61Q17/005—Antimicrobial preparations
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K8/00—Cosmetics or similar toiletry preparations
    • A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
    • A61K8/30—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds
    • A61K8/64—Proteins; Peptides; Derivatives or degradation products thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61Q—SPECIFIC USE OF COSMETICS OR SIMILAR TOILETRY PREPARATIONS
    • A61Q19/00—Preparations for care of the skin
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • C07K14/4701—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals not used
    • C07K14/4723—Cationic antimicrobial peptides, e.g. defensins
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
    • G01N2333/435—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans
    • G01N2333/46—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans from vertebrates
    • G01N2333/47—Assays involving proteins of known structure or function as defined in the subgroups
    • G01N2333/4701—Details
    • G01N2333/4721—Cationic antimicrobial peptides, e.g. defensins

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Immunology (AREA)
  • Molecular Biology (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Biomedical Technology (AREA)
  • Hematology (AREA)
  • Urology & Nephrology (AREA)
  • Organic Chemistry (AREA)
  • Biochemistry (AREA)
  • Food Science & Technology (AREA)
  • Dermatology (AREA)
  • General Physics & Mathematics (AREA)
  • Analytical Chemistry (AREA)
  • Physics & Mathematics (AREA)
  • Pathology (AREA)
  • Microbiology (AREA)
  • Cell Biology (AREA)
  • Biotechnology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • General Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Epidemiology (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Birds (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Zoology (AREA)
  • Toxicology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pain & Pain Management (AREA)
  • Rheumatology (AREA)
PT98942796T 1997-08-29 1998-08-28 Defensina humana def-x, gene e cdna, composicao que os contem e aplicacoes ao diagnostico e a terapia PT1009767E (pt)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
FR9710823A FR2767832B1 (fr) 1997-08-29 1997-08-29 Polypeptide defensine humaine def-x, adn genomique et adnc, composition les contenant et applications au diagnostic et au traitement therapeutique

Publications (1)

Publication Number Publication Date
PT1009767E true PT1009767E (pt) 2005-02-28

Family

ID=9510617

Family Applications (1)

Application Number Title Priority Date Filing Date
PT98942796T PT1009767E (pt) 1997-08-29 1998-08-28 Defensina humana def-x, gene e cdna, composicao que os contem e aplicacoes ao diagnostico e a terapia

Country Status (11)

Country Link
US (3) US6329340B1 (pt)
EP (1) EP1009767B1 (pt)
JP (1) JP2001514264A (pt)
AT (1) ATE284414T1 (pt)
AU (1) AU759482B2 (pt)
CA (1) CA2299560C (pt)
DE (1) DE69828063T2 (pt)
ES (1) ES2230714T3 (pt)
FR (1) FR2767832B1 (pt)
PT (1) PT1009767E (pt)
WO (1) WO1999011663A1 (pt)

Families Citing this family (17)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6984622B2 (en) * 1998-03-25 2006-01-10 The Regents Of The University Of California Use of lipopolysaccharides to manage corneal infections and wounds
US6335318B1 (en) * 1999-05-10 2002-01-01 The Regents Of The University Of California Antimicrobial theta defensins and methods of using same
WO2003070176A2 (en) * 2002-02-19 2003-08-28 The Government Of The United States Of America As Represented By The Secretary Of The Department Of Health And Human Services Modified defensins and their use
US7119070B2 (en) 2002-04-30 2006-10-10 The Regents Of The University Of California Antimicrobial theta defensins, analogs thereof, and methods of use
US20040096820A1 (en) * 2002-05-31 2004-05-20 Ciphergen Biosystems, Inc. Comparative proteomics of progressor and nonprogressor populations
CA2487895A1 (en) * 2002-05-31 2003-12-11 Ciphergen Biosystems, Inc. Defensins: use as antiviral agents
AU2003247667A1 (en) 2002-07-01 2004-01-19 University Of Rochester Medical Center Method for determination of likelihood of occurrence of preterm labor in pregnant females
GB0223655D0 (en) * 2002-10-10 2002-11-20 Mabtech Ab Method of diagnosis
KR20050089827A (ko) * 2002-12-19 2005-09-08 이츠차크 힐만 항균성 펩티드 억제물을 통한 질환 치료
EP1613966A2 (en) * 2003-04-08 2006-01-11 Colotech A/S A method for detection of colorectal cancer in human samples
US8202835B2 (en) 2005-06-17 2012-06-19 Yitzchak Hillman Disease treatment via antimicrobial peptides or their inhibitors
US9044438B2 (en) 2005-06-17 2015-06-02 Yitzchak Hillman Disease treatment via antimicrobial peptides or their inhibitors
US10967031B2 (en) 2010-12-28 2021-04-06 Kamedis Ltd. Synergistic herbal compositions with prebiotic properties for treatment of skin infections, allergies and inflammation
ES2645245T3 (es) 2010-12-28 2017-12-04 Kamedis Ltd. Extractos vegetales para el tratamiento y prevención de infecciones
WO2015195677A1 (en) 2014-06-18 2015-12-23 Medicell Technologies, Llc Stem cell stimulating compositions and methods
RU2597789C2 (ru) * 2014-11-10 2016-09-20 Илья Владимирович Духовлинов Анальгетическое средство на основе плазмидной днк, кодирующей hnp-1, либо hnp-2, либо hnp-3 (варианты)
WO2024036134A2 (en) * 2022-08-08 2024-02-15 Sri International Defensin proteins for infection assessment

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5032574A (en) * 1988-05-26 1991-07-16 Invitron Corporation Novel antimicrobial peptide
US5242902A (en) * 1989-09-06 1993-09-07 The Regents Of The University Of California Defensin peptide compositions and methods for their use
WO1993024513A1 (en) * 1992-05-22 1993-12-09 The Children's Hospital Of Philadelphia Gastrointestinal defensins, cdna sequences and method for the production and use thereof
US5459235A (en) * 1993-03-19 1995-10-17 The Regents Of The University Of California Antimicrobial peptides antibodies and nucleic acid molecules from bovine neutrophils
US5550109A (en) * 1994-05-24 1996-08-27 Magainin Pharmaceuticals Inc. Inducible defensin peptide from mammalian epithelia

Also Published As

Publication number Publication date
FR2767832B1 (fr) 2001-08-10
AU759482B2 (en) 2003-04-17
JP2001514264A (ja) 2001-09-11
US20020182703A1 (en) 2002-12-05
DE69828063T2 (de) 2005-12-01
CA2299560A1 (fr) 1999-03-11
AU9079898A (en) 1999-03-22
FR2767832A1 (fr) 1999-03-05
WO1999011663A1 (fr) 1999-03-11
CA2299560C (fr) 2012-03-20
EP1009767B1 (fr) 2004-12-08
ATE284414T1 (de) 2004-12-15
ES2230714T3 (es) 2005-05-01
US7105651B2 (en) 2006-09-12
DE69828063D1 (de) 2005-01-13
EP1009767A1 (fr) 2000-06-21
US20020115151A1 (en) 2002-08-22
US6960441B2 (en) 2005-11-01
US6329340B1 (en) 2001-12-11

Similar Documents

Publication Publication Date Title
PT1009767E (pt) Defensina humana def-x, gene e cdna, composicao que os contem e aplicacoes ao diagnostico e a terapia
Rowe Treatment of acute myelogenous leukemia in older adults
UA66417C2 (en) Recombinant adenovirus affecting canines, pharmaceutical composition
TR200103560T2 (tr) Göğüs kanserinin teşhis ve tedavisi için bileşimler ve bunların kullanımı
BR0012069A (pt) Composições e métodos para a terapia e diagnóstico de câncer pulmonar
BR0110091A (pt) Composições e processos para terapia e diagnóstico de câncer de mama
BR9907259A (pt) Compostos para terapia e diagnóstico de câncer de pulmão e processos para o seu uso
WO2000060077A3 (en) Compounds for therapy and diagnosis of lung cancer and methods for their use
TR200200938T2 (tr) CCR5 modülatörleri olarak piperidinler
DK0836485T3 (da) Kaskade-polymer-komplekser, fremgangsmåde til deres fremstilling og farmaceutiske midler indeholdende disse
EP1767636A3 (en) Compounds for immunotherapy and diagnosis of colon cancer and methods for their use
BR0110049A (pt) Agonista de cxcr4, uso de um agonista de cxcr4, e composição farmacêutica
IT1298487B1 (it) Composizioni farmaceutiche comprendenti pentraxina lunga ptx3 per la terapia di patologie di tipo infettivo, infiammatorio o tumorale,
Fowler et al. Community-acquired methicillin-resistant Staphylococcus aureus pyomyositis in an intravenous drug user
EP1019084A4 (en) NEW ANTIMICROBIAL POLYPEPTIDES AND METHOD FOR THEIR USE.
Niederle et al. Long-term treatment of chronic myelogenous leukemia with different interferons: results from three studies
WO2001049716A3 (en) Compounds for immunotherapy and diagnosis of colon cancer and methods for their use
CA2294566A1 (en) Ikk-.alpha. proteins, nucleic acids and methods
BRPI0410470A (pt) uso de uma eritropoietina ou de uma citocina protetora de tecido e método para proteger ou manter a viabilidade de uma célula, tecido ou órgão de mamìfero respondente
BR9707142A (pt) Polinucleotìdeo purificado, dna, vetor, célula hospedeira, linhagem celular de hibridoma, anticorpo monoclonal, processos para produzir exodus, para aumentar a resistência à infecção por vìrus de imonudeficiência humana (hiv), para tratamento de infecção por vìrus de imonodeficiência humana (hiv), para proteção de células progenitoras de medula óssea contra os efeitos citotóxicos e para tratamento de doenças mieloproliferativas, e, uso de produto de proteina de exodus.
Norazah et al. Molecular fingerprinting of fusidic acid-and rifampicin-resistant strains of methicillin-resistant Staphylococcus aureus (MRSA) from Malaysian hospitals
PT1007717E (pt) Processos e composicoes para terapias do cancro,utilizando genes que codificam o interferao-beta
BRPI0408468A (pt) métodos para preparação e uso de 1(alfa),24(s)-diidroxivitamina d2
BR9911944A (pt) Proteìna inibidora da quimiotaxia do staphylococcus (proteìna chips) e sua utilização
WO1999054463A3 (en) Human k+ ion channel and therapeutic applications thereof